Emerging insights into the role of BDH1 in the pathogenesis of human cancer - Summary - MDSpire

Emerging insights into the role of BDH1 in the pathogenesis of human cancer

  • By

  • Penghui Wang

  • Yunmeng Yan

  • Zhengrong Liu

  • Guoxun Feng

  • Wei Yu

  • June 3, 2026

  • 0 min

Share

Objective:

To elucidate the role of BDH1 in cancer metabolism and its potential as a prognostic biomarker and therapeutic target, emphasizing its significance in cancer progression.

Key Findings:
  • BDH1 is involved in the metabolism of ketone bodies, catalyzing the conversion of β-hydroxybutyrate (BHB) to acetoacetate (AcAc) across various cancer types.
  • Dysregulation of BDH1 is associated with tumor microenvironment adaptation, malignant progression, and differential therapeutic responses.
  • BDH1 functions as a metabolic rheostat in cancers, influencing energy production, epigenetic reprogramming, and microenvironment adaptation.
Interpretation:

BDH1's role in cancer metabolism suggests it could serve as a prognostic biomarker and a target for therapeutic strategies, with implications for clinical applications.

Limitations:
  • The review does not provide experimental data to support the proposed roles of BDH1 in cancer.
  • Further studies are needed to clarify the exact mechanisms by which BDH1 influences tumor behavior and to validate its clinical utility.
Conclusion:

BDH1's involvement in cancer metabolism highlights its potential as a target for precision oncology, suggesting avenues for future research and clinical application.

Original Source(s)

Emerging insights into the role of BDH1 in the pathogenesis of human cancer

  • by Penghui Wang, Yunmeng Yan, Zhengrong Liu, Guoxun Feng, Wei Yu

  • June 3, 2026

Related Content

SEZ6-targeting antibody−drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial

Automated bone marrow cell classification using ensemble learning: performance, generalization, and clinical interpretability

Perioperative Apalutamide in High-Risk Localized or Locally Advanced Prostate Cancer Reduces Risk of Metastasis and Death

High-risk localized and locally advanced prostate cancer patients treated with apalutamide — a next generation neoadjuvant androgen-receptor pathway inhibitor (ARPI) — plus hormone therapy before and after prostate cancer surgery resulted in more major pathologic responses and reduced the risk of metastasis or death, meeting both primary endpoints, in an international phase 3 clinical trial led by principal investigator Mary-Ellen Taplin, MD, medical oncologist at Dana-Farber Cancer Institute, and Adam Kibel, MD, chair of the Department of Urology at Mass General Brigham.

  • June 1, 2026

  • 4 min